<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770040</url>
  </required_header>
  <id_info>
    <org_study_id>HREC/14/Austin/595</org_study_id>
    <nct_id>NCT02770040</nct_id>
  </id_info>
  <brief_title>Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis</brief_title>
  <acronym>PREDICT-UC</acronym>
  <official_title>PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify whether an Accelerated or Intensified Infliximab&#xD;
      induction regimen is superior to Standard induction in Acute Severe Ulcerative Colitis in an&#xD;
      open label multi-centre randomised controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colectomy free survival</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Day 14</time_frame>
    <description>defined as a reduction in the Lichtiger score below 10 with a decrease of at least 3 points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Absence of clinical response at day 7&#xD;
Relapse between day 7 and 90 (defined as a Lichtiger score increase of at least 3 points from the previous value that lasts for at least 3 consecutive days and leads to treatment modification)&#xD;
A severe adverse event leading to treatment interruption&#xD;
Colectomy by day 90&#xD;
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in daily Lichtiger score</measure>
    <time_frame>From day 0 to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid free remission</measure>
    <time_frame>Day 90</time_frame>
    <description>defined as a Mayo disease activity index score ≤2 with an endoscopic subscore ≤1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission rate</measure>
    <time_frame>Day 90</time_frame>
    <description>defined as a Mayo endoscopic subscore of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission rate</measure>
    <time_frame>12 months</time_frame>
    <description>defined as a Mayo endoscopic subscore of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colectomy free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Intensified Infliximab Induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infliximab 10mg/kg at Week 0 and Week 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated Infliximab Induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infliximab 5mg/kg at Week 0, Week 1 and Week 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Infliximab Induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infliximab 5mg/kg at Week 0, Week 2 and Week 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused</description>
    <arm_group_label>Accelerated Infliximab Induction</arm_group_label>
    <arm_group_label>Intensified Infliximab Induction</arm_group_label>
    <arm_group_label>Standard Infliximab Induction</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Diagnosis of Ulcerative Colitis&#xD;
&#xD;
          -  Acute Severe Colitis according to the Truelove and Witt's Criteria&#xD;
&#xD;
          -  Steroid refractory according to the Oxford Criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant unable to consent for themselves&#xD;
&#xD;
          -  Indication for immediate surgery (acute abdomen, perforation of the bowel,&#xD;
             haemorrhage)&#xD;
&#xD;
          -  Crohn's disease&#xD;
&#xD;
          -  Participants with enteric infection confirmed on stool microscopy, culture or toxin&#xD;
&#xD;
          -  Haemodynamic instability (mean arterial pressure &lt;60) and not responsive to fluids&#xD;
&#xD;
          -  Participants with clinically significant Cytomegalovirus infection (positive inclusion&#xD;
             bodies, immunohistochemistry and signs of viraemia such as fever and abnormal liver&#xD;
             function tests)&#xD;
&#xD;
          -  Participants who are pregnant or currently breast-feeding&#xD;
&#xD;
          -  Participants with current malignancy, excluding basal cell carcinoma&#xD;
&#xD;
          -  Participants with flat low or high grade colonic dysplasia; sporadic adenomas&#xD;
             permitted&#xD;
&#xD;
          -  Participants with serious co-morbidities including: Immunodeficiency; Myocardial&#xD;
             infarction or acute stroke within the last 3 months; Moderate or severe heart failure&#xD;
             (New York Heart Association class III or IV); Active or suspected tuberculosis; Renal&#xD;
             failure; Hepatic failure; other severe infections&#xD;
&#xD;
          -  Participants with history of hypersensitivity to infliximab or infliximab biosimilar&#xD;
&#xD;
          -  Participants who have received other immunosuppressive agents including but not&#xD;
             limited to: Anti-TNF therapies within 3 months of screening (Infliximab, Infliximab&#xD;
             biosimilar, Golimumab, Etanercept, Certolizumab or Adalimumab); Anti-integrins&#xD;
             (Vedolizumb, Etrolizumab) within 4 months of screening; Calcineurin inhibitors&#xD;
             (Cyclosporine, Tacrolimus) within 4 weeks of screening; T or B cell depleters&#xD;
             (Rituximab, Alemtuzumab) within 12 months of screening; other investigational agents&#xD;
             (eg. Ustekinumab) within 6 months of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter De Cruz, MBBS PhD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Health, Melbourne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew C Choy, MBBS BMedSci FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Health, Melbourne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Austin Health</investigator_affiliation>
    <investigator_full_name>Dr Peter De Cruz</investigator_full_name>
    <investigator_title>Head of Inflammatory Bowel Disease Unit</investigator_title>
  </responsible_party>
  <keyword>Acute Severe Ulcerative Colitis</keyword>
  <keyword>Steroid Refractory Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

